Bavituximab Activates CD8+TILs in a 3D Ex Vivo System of Lung Cancer Patients Derived Tumors With Negative PD-L1 Expression

被引：0
|
作者：
Altiok, Soner [1 ]
Valera, Melanie Mediavilla [1 ]
Kreahling, Jenny [1 ]
Kallinteris, Nikoletta L. [2 ]
Noyes, David [3 ]
Razabdouski, Tiffany N. [3 ]
Shan, Joseph [2 ]
Hutchins, Jeff [2 ]
Menander, Kerstin [2 ]
Antonia, Scott J. [3 ]
机构：
[1] Nilogen Oncosyst, Tampa, FL USA
[2] Peregrine Pharmaceut, Clin, Tustin, CA USA
[3] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
Tumor microenvironment immunomodulation; 3D tumor microspheres; Chimeric monoclonal antibody-targeted therapy; Cytokine and immne function genes profiling-TILs activation;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MINI14.07
引用
收藏
页码：S312 / S313
页数：2
相关论文
共 50 条
  • [1] Bavituximab modulates tumor microenvironment and activates CD8+tumor infiltrating lymphocytes in a patient-derived 3D ex vivo system of lung cancer
    Altiok, Soner
    Mediavilla-Valera, Melanie
    Kreahling, Jenny
    Noyes, David
    Razabdouski, Tiffany N.
    Kallinteris, Nikoletta L.
    Shan, Joseph
    Antonia, Scott
    CANCER RESEARCH, 2015, 75
  • [2] Radiomic CT Features for Evaluation of PD-L1, CD8+TILs and Foxp3+TILs Expression in Stage I NSCLC
    Wen, Q.
    Linlin, W.
    Jian, Z.
    Tong, B.
    Yong, Y.
    Xindong, S.
    Jinming, Y.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S1155 - S1155
  • [3] Activation of CD8+tumor infiltrating lymphocytes by bavituximab in a 3D ex vivo system of lung cancer patients.
    Altiok, Soner
    Valera, Melanie Mediavilla
    Kreahling, Jenny
    Noyes, David
    Razabdouski, Tiffany N.
    Kallinteris, Nikoletta L.
    Shan, Joseph
    Antonia, Scott Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] CT Radiomics Features for Evaluation of PD-L1, CD8+TILs and Foxp3+TILs Expression Status in Patients with Stage I NSCLC
    Wen, Q.
    Meng, X.
    Zhu, J.
    Yin, Y.
    Yu, J.
    MEDICAL PHYSICS, 2017, 44 (06)
  • [5] Radiomic CT Features for Evaluation of PD-L1, CD8+TILs and Foxp3+TILs Expression Status in Patients with Stage I NSCLC
    Wen, Q.
    Meng, X.
    Zhu, J.
    Wang, S.
    Sun, X.
    Yu, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E738 - E738
  • [6] Deciphering the tumor microenviroment based on PD-L1 expression and CD8+TILs density in LA-NSCLC
    Kaesmann, L.
    Gennen, K.
    Taugner, J.
    Eze, C.
    Karin, M.
    Roengvoraphoj, O.
    Neumann, J.
    Tufman, A.
    Orth, M.
    Reu, S.
    Belka, C.
    Manapov, F.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S533 - S533
  • [7] The relationships between PD-L1 expression, CD8+TILs and clinico-histomorphological parameters in malignant melanomas
    Skuciova, V
    Drahosova, S.
    Vybohova, D.
    Cigerova, V
    Adamkov, M.
    PATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (09)
  • [8] Chemoradiation-induced altered profile of PD-L1 and CD8+TILs indicated prognosis in rectal cancer
    Lim, Y. J.
    Koh, J.
    Kim, S.
    Jeon, S. R.
    Chie, E. K.
    Kim, K.
    Kang, G. H.
    Han, S. W.
    Kim, T. Y.
    Jeong, S. Y.
    Park, K. J.
    Wu, H. G.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S6 - S6
  • [9] Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions
    Teng, Feifei
    Meng, Xiangjiao
    Wang, Xin
    Yuan, Jupeng
    Liu, Sujing
    Mu, Dianbin
    Zhu, Hui
    Kong, Li
    Yu, Jinming
    ONCOTARGET, 2016, 7 (39) : 64318 - 64329
  • [10] Prognostic value and clinicopathological status of PD-L1 expression and CD8+TILs in oral squamous cell cancer patients with or without traditional risk factors
    Soopanit, Thanion
    Laokulrath, Natthawadee
    Chayopasakul, Veeruth
    Pongsapich, Warut
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2023, 45 (04): : 1017 - 1025
12345